Endo Int'l (ENDP) Tops Q1 EPS by 11c; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Endo Int'l (ENDP) Tops Q1 EPS by 11c; Boosts FY15 EPS Outlook
May 11, 2015 7:01 AM EDT
RALEIGH, N.C., May 11, 2015 /PRNewswire/ --Â
BUNAVAIL® (buprenorphine and naloxone) buccal film showed a 25% average month-over-month growth in prescription sales over the quarter along with significant managed care wins
BELBUCA (buprenorphine HCl) buccal film for treatment of chronic pain PDUFA date of October 23, 2015 associated with $50 million milestone if approved
$10 million milestone payment received from Endo Pharmaceuticals in conjunction with NDA acceptance for BELBUCA
Clonidine Topical Gel Phase 3 data analysis complete; Pathway forward identified   Â
Buprenorphine Depot Injection for the maintenance treatment of opioid dependence and chronic pain on track for... More
May 11, 2015 7:00 AM EDT
DUBLIN, May 11, 2015 /PRNewswire/ --
First quarter revenues of $714 million
First quarter reported $0.85 diluted (GAAP) EPS from continuing operations and $1.17 adjusted diluted EPS from continuing operations
U.S. Branded Pharmaceuticals first quarter revenues increase of 21 percent primarily attributable to the acquisition of Auxilium Pharmaceuticals
U.S. Generic Pharmaceuticals continues strong growth in first quarter with 68 percent revenue increase over first quarter 2014
International Pharmaceuticals first quarter results on-track and aligned with Company expectations
Affirms revenue guidance from...
More
